CAR-CD19 T cells

BIOLOGICAL2 trials

Sponsors

RenJi Hospital, CARsgen Therapeutics Co., Ltd.

Conditions

CD19 Positive Malignant B-cell Leukemia and LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma

Phase 1

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

RenJi HospitalCD19 Positive Malignant B-cell Leukemia and Lymphoma

Start: 2016-10-31End: 2020-01-31Target: 45Updated: 2016-10-14

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

CompletedNCT03994913

CARsgen Therapeutics Co., Ltd.Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma

Start: 2019-08-14End: 2021-05-27Updated: 2023-04-14